![]() | |
Clinical data | |
---|---|
Trade names | Emrok |
Other names | (S)-(-)-Nadifloxacin |
Routes of administration | Parenteral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H21FN2O4 |
Molar mass | 360.385 g·mol−1 |
3D model ( JSmol) | |
| |
|
Levonadifloxacin (trade name Emrok) is an antibiotic drug of the fluoroquinolone class. [1] [2] Chemically, it is the (S)- enantiomer of the racemic drug nadifloxacin.
It is approved in India for the treatment of skin and soft tissue infections of Gram-positive bacteria. [3] It is also being studied for potential use against resistant strains of bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. [4]
Levonadifloxacin has poor oral bioavailability. A prodrug of levonadifloxacin with high oral bioavailability, alalevonadifloxacin, has been developed to mitigate this problem. [5]
![]() | |
Clinical data | |
---|---|
Trade names | Emrok |
Other names | (S)-(-)-Nadifloxacin |
Routes of administration | Parenteral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H21FN2O4 |
Molar mass | 360.385 g·mol−1 |
3D model ( JSmol) | |
| |
|
Levonadifloxacin (trade name Emrok) is an antibiotic drug of the fluoroquinolone class. [1] [2] Chemically, it is the (S)- enantiomer of the racemic drug nadifloxacin.
It is approved in India for the treatment of skin and soft tissue infections of Gram-positive bacteria. [3] It is also being studied for potential use against resistant strains of bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. [4]
Levonadifloxacin has poor oral bioavailability. A prodrug of levonadifloxacin with high oral bioavailability, alalevonadifloxacin, has been developed to mitigate this problem. [5]